Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Wockhardt Limited ( (IN:WOCKPHARMA) ) just unveiled an announcement.
Wockhardt has reported that its novel intravenous antibiotic Foviscu (WCK 4282) met the primary endpoint in a pivotal Phase 3 trial for complicated urinary tract infections and acute pyelonephritis caused by Gram-negative bacteria, including ESBL-producing strains, demonstrating a clinical cure rate of 93.23% and therapeutic equivalence to the carbapenem meropenem with a comparable safety profile. As the fifth proprietary antibiotic from Wockhardt to successfully complete a registration-enabling Phase 3 study, Foviscu is positioned as a potential first-line alternative to carbapenems in a market with high ESBL prevalence and growing resistance to commonly used agents, potentially easing pressure on last-line therapies, improving antibiotic stewardship, and reinforcing Wockhardt’s leadership in the antibiotic discovery space, particularly in India where millions of treatment courses of broad-spectrum antibiotics are used annually.
More about Wockhardt Limited
Wockhardt Limited is an Indian pharmaceutical and biotechnology company with a strong focus on anti-infectives, particularly novel antibiotics targeting drug-resistant bacterial infections. The company has built a portfolio of proprietary antibiotics, including Emrok, Emrok O, Miqnaf and Zaynich, positioning itself as a notable player in antibiotic discovery and addressing unmet medical needs in hospital-acquired and complicated infections.
Average Trading Volume: 76,246
Technical Sentiment Signal: Buy
Current Market Cap: 218.7B INR
For a thorough assessment of WOCKPHARMA stock, go to TipRanks’ Stock Analysis page.